BioCentury
ARTICLE | Clinical News

Atrix begins four-month Leuprogel trial

January 29, 2001 8:00 AM UTC

ATRX began a Phase III trial of its Leuprogel four-month, 30 mg leuprolide acetate subcutaneous depot injection to treat advanced prostate cancer. Leuprogel is also in Phase III testing as a monthly i...